Latest Cancer TreatmentsDr. Mohammadreza Dabiri
Dr. Mohammadreza Dabiriفارسی
Physician lesson

Febrile neutropenia: assessment, empirical antibiotics and outpatient treatment

Step by step from the first hour to stopping antibiotics (IDSA, ESMO and ASCO)

Updated: 28 October 20261 min read4 references

Key points

  • A broad-spectrum antibiotic within 60 minutes of arrival [2].
  • Monotherapy with an antipseudomonal beta-lactam is enough; vancomycin only with an indication [1].
  • Low-risk patients (MASCC 21 or more) can be treated as outpatients [3, 4].
  • Persistent fever after 4 to 7 days in high-risk patients: empirical or pre-emptive antifungal treatment [1].

The first hour

  1. 1

    Know the definition

    A temperature of 38.3 °C, or 38 °C sustained for an hour, with an ANC below 500 or expected to fall below it [1]. Neutropenic patients may be septic without fever, presenting only with hypotension or confusion.

  2. 2

    Assessment

    Two sets of blood cultures (one from the catheter), urine culture and cultures from suspicious sites, blood count, creatinine, liver enzymes, lactate; chest X-ray with respiratory symptoms [1, 2].

  3. 3

    Empirical antibiotic

    Cefepime, piperacillin-tazobactam or a carbapenem (meropenem, imipenem) [1]; chosen according to local resistance patterns and previous colonisation (ESBL, CRE).

  4. 4

    Assess the risk

    MASCC and, in stable solid tumours, CISNE [3].

When should another drug be added?

Additions to empirical treatment [1, 2]
SituationAdd
Haemodynamic instability, catheter or skin and soft tissue infection, pneumonia, MRSA colonisation, gram-positive cocci in cultureVancomycin (or another anti-gram-positive drug)
Septic shock or suspected resistanceAn aminoglycoside and broader cover (carbapenem)
Persistent fever for 4 to 7 days in high-risk, prolonged neutropeniaEmpirical antifungal or pre-emptive assessment (lung CT, galactomannan)
Diarrhoea with abdominal painAnaerobic cover; Clostridioides difficile testing

Duration of treatment

If no source is found, continue until the patient has been afebrile for at least 48 hours and the ANC is above 500; with a known source, for the time needed for that infection [1]. ESMO allows earlier stopping in afebrile, stable patients, even before ANC recovery, with close monitoring [2].

Outpatient treatment

The criteria and oral regimen are on the MASCC page [3].

References

4 references
Show all references, 3 with a study cardClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of americaFreifeld AG, Bow EJ, Sepkowitz KA, et al · Clin Infect Dis · 2011;52:e56-93
    Study cardDOIPubMed Back to text: 1 2 3 4 5 6 7
  2. 2
    Management of febrile neutropaenia: ESMO Clinical Practice GuidelinesKlastersky J, de Naurois J, Rolston K, et al · Ann Oncol · 2016;27:v111-v118
    Study cardDOIPubMed Back to text: 1 2 3 4
  3. 3
    Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline UpdateTaplitz RA, Kennedy EB, Bow EJ, et al · J Clin Oncol · 2018;36:1443-1453
    Study cardDOIPubMed Back to text: 1 2 3
  4. 4
    The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patientsKlastersky J, Paesmans M, Rubenstein EB, et al · J Clin Oncol · 2000;18:3038-51
    DOIPubMed Back to text

This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.

Printed from the website; the full and up-to-date version: https://drdabiri.com/en/learn/febrile-neutropenia-management/

Related pages

27 October 2026 DPYD, UGT1A1 and TPMT/NUDT15 testing before chemotherapy A guide to DPYD testing before fluorouracil and capecitabine, UGT1A1 before irinotecan and TPMT/NUDT15 before mercaptopurine, with genotype-guided dosing. 27 October 2026 Hepatitis B and chemotherapy: screening and prevention of reactivation A guide to hepatitis B screening before chemotherapy, rituximab and transplant, reactivation risk groups, and prophylaxis with entecavir or tenofovir. 27 October 2026 Infection prevention and vaccination in cancer patients A guide to antimicrobial prophylaxis (fluoroquinolone, posaconazole, co-trimoxazole, aciclovir) and vaccination (influenza, pneumococcus, shingles, COVID-19) in cancer patients based on ASCO and IDSA.